Efficacy of mouth rinse in preventing oral mucositis in patients receiving high-dose cytarabine for allogeneic hematopoietic stem cell transplantation
- 30 October 2008
- journal article
- Published by Springer Nature in International Journal of Hematology
- Vol. 88 (5) , 583-587
- https://doi.org/10.1007/s12185-008-0181-5
Abstract
High-dose cytarabine is one of the major components of the conditioning regimen for hematopoietic stem cell transplantation (HSCT), and frequently causes severe oral mucositis. We have recently demonstrated that cytarabine is excreted into the saliva in patients receiving high-dose cytarabine, and proposed that it might locally and directly contribute to the development of oral mucositis. Therefore, this study was performed to assess whether removing the excreted cytarabine in the saliva by intensive mouth rinse during high-dose cytarabine infusion could reduce the incidence of oral mucositis. Fifteen patients with hematologic malignancies undergoing allogeneic HSCT who received total body irradiation (12 Gy) and high-dose cytarabine at a dose of 3 g/m2 every 12 h for 4 days as a conditioning were evaluated. Patients were instructed to rinse their mouths using ice-cold water every 10 min, starting simultaneously with the 2-h cytarabine infusion and continuing up to 1 h after completion of each infusion. Oral mucositis was graded on a daily basis according to the National Cancer Institute, Common Toxicity Criteria. Thirty-five patients who previously underwent the same conditioning without mouth rinse served as controls. The incidence of Grades 2–3 and Grade 3 oral mucositis was significantly reduced in patients who performed mouth rinse as compared with the controls (40 vs. 80%, P = 0.009; 0 vs. 25. 7%, P = 0.02). In conclusion, mouth rinse during and shortly after high-dose cytarabine infusion could be an effective and inexpensive measure in reducing the incidence of moderate to severe oral mucositis caused by high-dose cytarabine. This finding strongly suggests the role of cytarabine excretion in the saliva in the development of cytarabine-associated oral mucositis.Keywords
This publication has 25 references indexed in Scilit:
- Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experienceBone Marrow Transplantation, 2007
- Excretion of cytosine arabinoside in saliva after its administration at high dosesAnti-Cancer Drugs, 2006
- Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipientsSupportive Care in Cancer, 2006
- Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipientsSupportive Care in Cancer, 2005
- Greater risks of chemotherapy toxicity in elderly patients with cancer.2004
- Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatmentBone Marrow Transplantation, 2003
- Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis – are there new strategies?Bone Marrow Transplantation, 1999
- Ice pops to prevent melphalan-induced stomatitisThe Lancet, 1996
- Fractionated total‐body irradiation preceding high‐dose cytosine arabinoside as a preparative regimen for bone marrow transplantation in children with acute leukemiaMedical and Pediatric Oncology, 1995
- Toxicity of sequential high-dose ARA-C asparaginase treatment in childhood poor risk leukemiaAnnals of Hematology, 1986